Abstracts tagged "fractures"

Abstract Number: 2920 • 2017 ACR/ARHP Annual Meeting
Comparative Rates of Osteoporotic Fractures Among U.S. Medicaid Enrollees with and without Systemic Lupus Erythematosus
Sara K. Tedeschi¹, Beatrice Pan¹, Hongshu Guan¹, Seoyoung C. Kim², Daniel H. Solomon¹ and Karen H. Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Fractures are potentially avoidable and highly morbid. We studied non-vertebral fracture rates among SLE patients enrolled in Medicaid, the U.S. health insurance program for…
Abstract Number: 304 • 2017 ACR/ARHP Annual Meeting
Usefulness of Consecutive Doppler Ultrasound Examinations for Detecting Deep Venous Thrombosis during the Perioperative Period in Patients with Osteoporotic Fractures of the Proximal Femur
Ken Nakaseko and Norihiro Mayumi, Department of Orthopaedic Surgery and Rheumatology, Kuwana City Medical Center, Kuwana Mie, Japan
Background/Purpose: Deep venous thrombosis (DVT) can lead to a venous thromboembolism and increase the risk of a pulmonary thromboembolism (PE). PE is one of the…
Abstract Number: 318 • 2017 ACR/ARHP Annual Meeting
A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
Kenneth Saag¹, Jeffrey Petersen², Maria Luisa Brandi³, Andrew Karaplis⁴, Mattias Lorentzon⁵, Thierry Thomas⁶, Judy Maddox², Michelle Fan², Paul D. Meisner⁷ and Andreas Grauer², ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³University of Florence, Florence, Italy, ⁴McGill University, Montreal, QC, Canada, ⁵University of Gothenburg and Sahlgrenska University Hospital, Mölndal, Sweden, ⁶CHU de Saint-Étienne, Saint-Étienne, France, ⁷UCB Pharma, Brussels, Belgium
Background/Purpose: The bone forming agent romosozumab (Romo) was previously shown to reduce vertebral and clinical fractures in postmenopausal women with osteoporosis. Here we report the…
Abstract Number: 320 • 2017 ACR/ARHP Annual Meeting
Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial
Cristiano A.F Zerbini¹, Piet Geusens², Eric Lespessailles³, Jean-Jacques Body⁴, Enrique Casado⁵, Jan Stepan⁶, David L Kendler⁷, Luis Russo⁸, Susan L. Greenspan⁹, Salvatore Minisola¹⁰, Alicia Bagur¹¹, Peter Lakatos¹², Astrid Fahrleitner-Pammer¹³, Rüdiger Möricke¹⁴, Pedro Lopez-Romero¹⁵ and Fernando Marin¹⁶, ¹Centro Paulista de Investigações Clinicas, São Paulo, Brazil, ²Maastricht University Hospital, Maastricht, Netherlands, ³Service de Rhumatologie, CHR d'Orléans, Orléans, France, ⁴CHU Brugmann, Free University Brussels, Brussels, Belgium, ⁵Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ⁶Institute of Rheumatology, Faculty of Medicine 1, Charles University, Prague, Czech Republic, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Centro de Analises e Pesquisas Clínicas LTDA,, Rio de Janeiro, Brazil, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Internal Medicine, Policlinico Umberto I,, Rome, Italy, ¹¹Centro de Osteopatías Comlit, Buenos Aires, Argentina, ¹²Department of Medicine, Semmelweis University, Budapest, Hungary, ¹³Division of Endocrinology, Medical University, Graz, Austria, ¹⁴Institut Präventive Medizin & Klinische Forschung, Magdeburg, Germany, ¹⁵Europe Research Center, Eli Lilly and Company, Madrid, Spain, ¹⁶Lilly Research Center Europe, Madrid, Spain
Background/Purpose: The VERO trial was an active-controlled fracture endpoint clinical trial that recruited postmenopausal women with low bone mass and prevalent vertebral fractures (VFx). We…
Abstract Number: 326 • 2017 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures Are Associated with Disease Activity, Low Vitamin D Levels and Spinal Radiographic Damage in Patients with Axial Spondyloarthritis
Cintia Romera-López¹, Cristina Fernández-Carballido², Miguel Ángel García-Moreno³ and Teresa Pedraz⁴, ¹Rheumatology, Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Elda, Elda, Spain, ³Hosppital Universitario de Elda, Elda, Spain, ⁴Hospital Universitario de Elda, Elda, Spain
Background/Purpose: Osteoporosis and vertebral fractures are comorbidities of Axial Spondyloarthritis (axSpA). We evaluated the relationship between disease activity and radiographic damage and bone mineral density…
Abstract Number: 328 • 2017 ACR/ARHP Annual Meeting
Secular Trends in the Risk of Fragility Fracture Among Patients with Rheumatoid Arthritis: A General Population-Based Study
Sarah Keller¹, Marcy B. Bolster², Amar Oza³, Sharan K. Rai⁴, Leo Lu³, Yuqing Zhang⁵ and Hyon K. Choi⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The risk of osteoporotic (OP) fracture among patients with rheumatoid arthritis (RA) is higher than that of the general population. The worldwide incidence of…
Abstract Number: 1094 • 2017 ACR/ARHP Annual Meeting
A Model for Improved Management of Fragility Fractures: Navigating the Fracture Liaison Service
Marcy B. Bolster¹, Smriti Cevallos², Lisa Beyer², Henry M. Kronenberg² and Ben Leder², ¹Massachusetts General Hospital, Boston, MA, ²Endocrine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Fragility fractures are associated with significant morbidity, mortality and healthcare costs, yet most fracture patients are neither evaluated nor treated for their underlying osteoporosis…
Abstract Number: 1214 • 2017 ACR/ARHP Annual Meeting
Fracture Incidence and Characteristics in Young Adults Age 18 to 49 Years: A Population-Based Study
Joshua N. Farr¹, L. Joseph Melton III¹, Sara J. Achenbach¹, Elizabeth J. Atkinson¹, Sundeep Khosla¹ and Shreyasee Amin², ¹Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: While fractures in both the elderly and pediatric populations have been extensively investigated, comparatively little attention has been given to the age-group in between.…
Abstract Number: 337 • 2016 ACR/ARHP Annual Meeting
Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability
E Siris¹, N Pannacciulli², PD Miller³, EM Lewiecki⁴, R Chapurlat⁵, E Jódar-Gimeno⁶, NS Daizadeh², RB Wagman² and JA Kanis⁷, ¹Columbia University Medical Center, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Colorado Center for Bone Research, Lakewood, CO, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵Hôpital Edouard Herriot, Lyon, France, ⁶Hospital Universitario Quirónsalud Madrid, Madrid, Spain, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Denosumab is approved for treating postmenopausal women with osteoporosis at high risk for fracture. The placebo-controlled FREEDOM trial and its active-treatment Extension investigated the…
Abstract Number: 345 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Anti-Cyclic Citrullinated Peptide (anti-CCP) Levels and Bone Mineral Density (BMD) or Fragility Fracture in Patients with Rheumatoid Arthritis (RA)
Tien-Tsai Cheng^1,2, Yin-Chou Chen^1,2, Shan-Fu Yu^1,2, Han-Ming Lai^1,2, Ben Yu-Jih Su^1,2, Fu-Mei Su^2,3, Wen-Chan Chiu^1,2, Chung-Yuan Hsu^1,4, Jia-Feng Chen¹ and Chi-Hua Ko¹, ¹Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, ²Chang Gung University College of Medicine, Kaohsiung, Taiwan, ³Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, ⁴Division of Rheumatology, Allergy, and Immunology, Chang Gung University College of Medicine, Kaohsiung, Taiwan
Background/Purpose: To explore the relationship of anti-CCP levels with BMD or fragility fracture in patients with RA Methods: This is a prospective cross sectional study.…
Abstract Number: 895 • 2016 ACR/ARHP Annual Meeting
Incidence of Osteoporotic Mayor Fractures in a Cohort of Patients with Polymyalgia Rheumatica
Luciano Enrique Pompermayer¹, Ignacio Javier Gandino¹, Maximiliano José Martinez¹, Florencia Beatriz Mollerach¹, Marina Scolnik², Javier Rosa¹ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease associated with older age and long term use of glucocorticoids. As such a high incidence of osteoporosis…
Abstract Number: 1023 • 2016 ACR/ARHP Annual Meeting
Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
F Cosman¹, DB Crittenden², JD Adachi³, N Binkley⁴, E Czerwinski⁵, S Ferrari⁶, LC Hofbauer⁷, E Lau⁸, EM Lewiecki⁹, A Miyauchi¹⁰, CAF Zerbini¹¹, CE Milmont², L Chen², J Maddox², PD Meisner¹², C Libanati¹² and A Grauer², ¹Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University, Hamilton, ON, Canada, ⁴University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI, ⁵Krakow Medical Center, Krakow, Poland, ⁶Geneva University Hospital, Geneva, Switzerland, ⁷Division of Endocrinology, Diabetes, and Bone Diseases, TU Dresden Medical Center, Dresden, Germany, ⁸Center for Clinical and Basic Research, Hong Kong, China, ⁹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ¹⁰Miyauchi Medical Center, Osaka, Japan, ¹¹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹²UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here,…
Abstract Number: 1027 • 2016 ACR/ARHP Annual Meeting
Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial
Michael R. McClung¹, Bente Langdahl², Socrates Papapoulos³, Kenneth G. Saag⁴, Henry Bone⁵, Douglas P. Kiel⁶, Kurt Lippuner⁷, Toshitaka Nakamura⁸, Ian Reid⁹, Norman Heyden¹⁰, Carolyn DaSilva¹⁰, Boyd B. Scott¹⁰, Rachid Massaad¹¹, Keith D. Kaufman¹⁰, S. Aubrey Stoch¹⁰, Arthur Santora¹⁰, Deborah Gurner¹⁰ and Antonio Lombardi¹⁰, ¹Oregon Osteoporosis Center, Portland, OR, USA, Portland, OR, ²Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ³Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Michigan Bone & Mineral Clinic, Detroit, MI, USA and The Osteoporosis Center at St. Luke's Hospital, Chesterfield, MO, USA, Detroit, MI, ⁶Institute for Aging Research, Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, MA, USA, Boston, MA, ⁷Bern University Hospital, Bern, Switzerland, Bern, Switzerland, ⁸University of Occupational and Environmental Health, Fukuoka, Japan, Fukuoaka, Japan, ⁹University of Auckland, Auckland, New Zealand, Auckland, New Zealand, ¹⁰Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, ¹¹MSD Europe Inc., Brussels, Belgium, Brussels, Belgium
Background/Purpose: Long-Term Odanacatib Fracture Trial [Women 65 years of age with BMD T-score ≤–2.5 at total hip (TH) or femoral neck (FN), or with radiographic…
Abstract Number: 1028 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension
Jacques P Brown¹, S Ferrari², N Gilchrist³, Jens-Erik Beck Jensen⁴, N Pannacciulli⁵, Chris Recknor⁶, Christian Roux⁷, Shawna Smith⁵, Ove Törring⁸, Ivo Valter⁹, Rachel B Wagman⁵, A Wang⁵ and SR Cummings¹⁰, ¹Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³The Princess Margaret Hospital, Christchurch, New Zealand, ⁴Hvidovre University Hospital, Hvidovre, Denmark, ⁵Amgen Inc., Thousand Oaks, CA, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Paris Descartes University, Paris, France, ⁸Karolinska Institutet Sodersjukhuset, Stockholm, Sweden, ⁹Center for Clinical and Basic Research, Tallinn, Estonia, ¹⁰SFCC, CPMC Research Institute & UCSF, San Francisco, CA
Background/Purpose: Denosumab (DMAb) treatment has been shown to decrease fracture (Fx) risk. Unlike bisphosphonates, DMAb is a monoclonal antibody against RANKL. Discontinuation is characterized by…
Abstract Number: 1223 • 2016 ACR/ARHP Annual Meeting
The Cost of Confronting Osteoporosis:Cost Study of a Fracture Liaison Service
Gabor Major^1,2, Rod Ling^3,4, Andrew Searles^3,4, Fiona Niddrie⁵, Ayano Nakayama⁶, Elizabeth Holliday^4,7, John Attia^4,7 and Nikolai Bogduk^4,6, ¹Rheumatology, Bone and Joint Institute, John Hunter Hospital NSW Australia, Newcastle, Australia, ²Medicine, University of Newcastle, Newcastle, Australia, ³Health Economics, Hunter Medical Research Institute, Newcastle, Australia, ⁴University of Newcastle, Newcastle, Australia, ⁵Rheumatology, Bone and Joint Institute,John Hunter Hospital, Newcatle, Australia, ⁶Rheumatology, Bone and Joint Institute,John Hunter Hospital, Newcastle, Australia, ⁷Hunter Medical Research Institute, Newcastle, Australia
Background/Purpose: Services that actively seek out and identify patients with fractures following a minimal trauma injury have been promoted as the most effective means of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].